Loading clinical trials...
Loading clinical trials...
A Randomized, Open-label, Multi-center, Phase III Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Conditions
Interventions
MRG003 + Pucotenlimab
Gemcitabine, Docetaxel, or Capecitabine
Locations
1
China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Start Date
May 6, 2025
Primary Completion Date
May 1, 2029
Completion Date
December 1, 2030
Last Updated
January 20, 2026
NCT07258979
NCT06472713
NCT06241599
Lead Sponsor
Shanghai Miracogen Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions